Global Angina Pectoris Drugs Market Insights Forecasts to 2030
- The Global Angina Pectoris Drugs Market Size was valued at USD 11.2 Billion in 2021.
- The Market is Growing at a CAGR of 4.5% from 2021 to 2030.
- The Worldwide Angina Pectoris Drugs Market size is expected to reach USD 16.4 Billion by 2030.
- Asia Pacific is expected To Grow the fastest during the forecast period.
Get more details on this report -
The Global Angina Pectoris Drugs Market Size is expected to reach USD 16.4 Billion by 2030, at a CAGR 4.5% during the forecast period 2021 to 2030. The global angina pectoris drugs market is expected to be collectively driven by demand for disease-modifying and targeted treatments, increased expenditure on healthcare, and availability of effective treatment methods across the emerging markets.
Angina pectoris is a medical term for chest pain or discomfort, which is caused due to coronary heart disease. It mainly occurs when the heart muscle is unable to receive sufficient blood. This disease usually occurs when one or more of the heart’s arteries are restricted or obstructed, which is also known as myocardial ischemia. Microvascular dysfunction (MVD), which impacts the smaller blood vessels in the heart, coronary artery spasm, fixed epicardial coronary artery atherosclerotic blockage, and chronic types of angina are all possible causes of myocardial ischemia. Age has a significant impact on the prevalence of angina pectoris in both genders, ranging from 2.0–5.0% in men aged 45–54 to 10.0–20.0% in men aged 65–74 and from 0.1–1.0% in women aged 45–54 to 10.0–15.0% in women aged 65–74. Electrocardiograms and angiography are two ways to identify angina pectoris. Medication, a change in lifestyle, and surgery are all possible treatments. Angioplasty is a minimally invasive procedure also used to treat angina pectoris. The pain or discomfort caused by angina pectoris is relieved with rest and nitroglycerin. By increasing blood flow to the heart vessels, nitroglycerin relaxes other blood vessels as well as the coronary arteries.
This research report categorizes the global angina pectoris drugs market based on various segments and regions and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global angina pectoris drugs market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segments of the global angina pectoris drugs market. Technological innovation and advancement will further optimize the performance of the product, enabling it to acquire a wider range of applications in the downstream market.
Global Angina Pectoris Drugs Market Report Coverage
|Market Size in 2021:||USD 11.2 Billion|
|Forecast Period 2021-2030 CAGR:||4.5%|
|2030 Value Projection:||USD 16.4 Billion|
|Historical Data for:||2017-2020|
|No. of Pages:||200|
|Tables, Charts & Figures:||100|
|Segments covered:||By Drug, By End Users, By Region, COVID-19 Impact Analysis|
|Companies Covered:||Abbott Laboratories, AERIE PHARMACEUTICALS, INC., Abbvie, Inc.,Bausch Health Companies, Inc., Merck & Co. Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Amorphex Therapeutics Holdings, Inc., Alcon, Astellas Pharma Inc.,Bayer AG,Novartis AG, AstraZeneca, Amgen Inc., Carl Zeiss Meditec AG, Gilead Sciences, Inc., Sun Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd. , Zydus Healthcare|
|Pitfalls & Challenges:||COVID-19 Empact, Challenge, Future, Growth, & Analysis|
Get more details on this report -
The rise in the patient population suffering from cardiac disorders such as coronary heart disease is one of the main factors driving the market's growth. For example, according to data provided by the World Health Organization in December 2020, ischemic heart disease was the leading cause of death globally, accounting for 16% of all deaths. Moreover, the rising geriatric population is also contributed significantly to the growth of angina pectoris medicines and drugs all over the globe. Angina pectoris can affect any age group, but it's particularly more prevalent in people over the age of 60. As a result, a number of market segments and age groups have contributed to the demand for angina pectoris drugs on the global market. Furthermore, Increased approvals from FDA and more clinical research associated with angina pectoris are boosting the market growth. For instance, several gene therapy products in Phase II/III trials are developing as a novel approach to fulfil the demand for non-surgical cardiovascular treatments.
In the upcoming years, several factors could restrict the market growth of angina pectoris drugs, such as the increasing popularity of minimally invasive surgeries and the adverse effects associated with certain drug classes. Also, the high cost of therapy, as well as government rules and policies regarding drug patents, may hinder market expansion during the forecast period.
In 2021, the beta blockers segment is dominating the market with the largest market share over the forecast period.
Based on drug classes, the angina pectoris drug market is segmented into Beta Blockers, Calcium Channel Blockers, Nitrates, Angiotensin-converting Enzyme Inhibitors (ACE Inhibitors), Anti-Platelets, and Others. Among these, the beta blockers segment is expected to grow the market due to Beta-blockers decrease the heart rate and reduce the force that the heart muscles contract by inhibiting the effects of adrenaline on the heart. The target population is increasing, and more market competitors are implementing strategic plans to expand the commercial availability of beta-blocker medications, which are primarily responsible for the segment's growth. For example, in April 2022, Melinta Therapeutics received the rights to TOPROL-XL (metoprolol succinate) in the United States from New American Therapeutics. The FDA has approved TOPROL-XL, a cardio-selective beta-blocker, for the long-term therapy of angina pectoris as well as the treatment of stable, symptomatic heart failure of particular causes. Also, hypertension can be treated with TOPROL-XL alone or in combination with other antihypertensives drugs.
The calcium channel blockers hold the second-largest market share. Calcium channel blockers decrease arterial pressure by inhibiting calcium from entering the cells of your heart and arteries.
In 2021, The Hospital segment is dominating the market over the forecast period.
Based on the end user, the angina pectoris drugs market is bifurcated into hospitals pharmacies, pharmaceutical stores, and others. Throughout these segments, the hospital pharmacies held the largest share in the angina pectoris drugs market because hospitals with advanced infrastructure and appropriate facilities are treating an increasing number of people who have angina pectoris disorders. Furthermore, the increasing number of hospitals along with adequate policies is also contributing to the growth of this segment.
Regional Segment Analysis of the angina pectoris drugs market
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Rest of APAC)
- South America (Brazil and the Rest of South America)
- The Middle East and Africa (UAE, South Africa, Rest of MEA)
North America is dominating the largest market share of 42.9% during the forecast period
Get more details on this report -
North America accounts the largest market share of 42.9% during the forecast period in 2021, owing to its significant proportion due to the U.S. established healthcare system, increasing use of therapeutics, and the presence of important key manufacturers in the market. Also, the growing demand for minimally invasive procedures is expected to increase the growth rate of this market during the forecast period. Furthermore, the unhealthy lifestyles, favorable regulatory actions, and an increase in cardiac diseases, the market is also being driven.
Asia Pacific is expected to register a higher market growth during the forecast period due to lifestyle changes and the emerging economy of key countries such as India and China are expected to drive the market growth. China offers significant possibilities for market expansion owing to the removal of price restrictions on all drug categories, the continuing Healthy China 2020 healthcare reform, and supportive 12th Five-Year Plan policies that target biotechnology as a key development industry.
The report offers the appropriate analysis of the key organizations/companies involved within the global angina pectoris drug market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
List of Key Companies
- Abbott Laboratories,
- AERIE PHARMACEUTICALS, INC.
- Abbvie, Inc.
- Bausch Health Companies, Inc.
- Merck & Co. Inc.
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Amorphex Therapeutics Holdings, Inc.
- Astellas Pharma Inc.
- Bayer AG
- Novartis AG
- Amgen Inc.
- Carl Zeiss Meditec AG
- Gilead Sciences, Inc.
- Sun Pharmaceutical Industries Ltd.
- F. Hoffmann-La Roche Ltd.
- Zydus Healthcare
Key Target Audience
- Market Players
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
- In March 2022, the US Food and Drug Administration (FDA) approved Zydus Lifesciences to launch its Nitroglycerin Sublingual Tablets for angina in the 0.3 mg, 0.4 mg, and 0.6 mg strengths (US RLD: Nitrostat Sublingual Tablets).
This study forecasts revenue at global, regional, and country levels from 2019 to 2030. Spherical Insights has segmented the Global Angina Pectoris Drugs Market based on the below-mentioned segments:
Global Angina Pectoris Drugs Market, By Drug Class
- Beta Blockers
- Calcium Channel Blockers
- Angiotensin-converting Enzyme Inhibitors (ACE Inhibitors)
- Anti-Platelets, and Others
Global Angina Pectoris Drugs Market, By End User
- Hospital Pharmacy
- Pharmaceutical Stores
Global Angina Pectoris Drugs Market, By Regional Analysis
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- South America
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Need help to buy this report?